Latest Intelligence on Therapy Area in Sweden

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Meda: nasal steroid/antihistamine combination takes one step closer to market

The positive results of a second Phase III trial have added to the anticipation for Dymista, Meda's nasal steroid/antihistamine combination for allergic rhinitis. In line for first-to-market status, the combination will be a welcome addition to current treatment options.

Published By Datamonitor
23 Mar 2011
CommentWire
CommentWire

Alzheimer's disease: testing times for those at risk

Long-term studies have shown biomarkers to be effective in predicting those with mild cognitive impairment that will go on to develop Alzheimer's disease. Such a test could help companies developing new therapies for delaying or preventing the onset of Alzheimer's, and, by identifying the need for treatment early, could improve both drug uptake and treatment success rates.

Published By Datamonitor
07 Feb 2006
CommentWire
CommentWire

AstraZeneca: Arimidex is the new gold standard

The cancer drug showed outstanding results compared to the current gold standard, tamoxifen. Indeed, Arimidex could be the ideal aromatase inhibitor - and judging by these results, AstraZeneca's marketing power will ensure that the drug becomes a major cancer product.

Published By Datamonitor
19 Feb 2002
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001

« | 1 | » »|

No help is available.